Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Shigella-Controlled Human Infection Models: Current and Future Perspectives.
Clarkson KA, Porter CK, Talaat KR, Kapulu MC, Chen WH, Frenck RW Jr, Bourgeois AL, Kaminski RW, Martin LB. Clarkson KA, et al. Among authors: bourgeois al. Curr Top Microbiol Immunol. 2022 May 27. doi: 10.1007/82_2021_248. Online ahead of print. Curr Top Microbiol Immunol. 2022. PMID: 35616717
Consensus Report on Shigella Controlled Human Infection Model: Conduct of Studies.
Talaat KR, Bourgeois AL, Frenck RW, Chen WH, MacLennan CA, Riddle MS, Suvarnapunya AE, Brubaker JL, Kotloff KL, Porter CK. Talaat KR, et al. Among authors: bourgeois al. Clin Infect Dis. 2019 Dec 9;69(Suppl 8):S580-S590. doi: 10.1093/cid/ciz892. Clin Infect Dis. 2019. PMID: 31816068 Free PMC article.
The Controlled Human Infection Model for Enterotoxigenic Escherichia coli.
Porter CK, Talaat KR, Isidean SD, Kardinaal A, Chakraborty S, Gutiérrez RL, Sack DA, Bourgeois AL. Porter CK, et al. Among authors: bourgeois al. Curr Top Microbiol Immunol. 2021 Oct 21. doi: 10.1007/82_2021_242. Online ahead of print. Curr Top Microbiol Immunol. 2021. PMID: 34669040
Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity score.
Porter CK, Lynen A, Riddle MS, Talaat K, Sack D, Gutiérrez RL, McKenzie R, DeNearing B, Feijoo B, Kaminski RW, Taylor DN, Kirkpatrick BD, Bourgeois AL. Porter CK, et al. Among authors: bourgeois al. PLoS One. 2018 Mar 28;13(3):e0194325. doi: 10.1371/journal.pone.0194325. eCollection 2018. PLoS One. 2018. PMID: 29590182 Free PMC article.
Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccine.
Clarkson KA, Talaat KR, Alaimo C, Martin P, Bourgeois AL, Dreyer A, Porter CK, Chakraborty S, Brubaker J, Elwood D, Frölich R, DeNearing B, Weerts HP, Feijoo B, Halpern J, Sack D, Riddle MS, Fonck VG, Kaminski RW. Clarkson KA, et al. Among authors: bourgeois al. EBioMedicine. 2021 Apr;66:103308. doi: 10.1016/j.ebiom.2021.103308. Epub 2021 Apr 1. EBioMedicine. 2021. PMID: 33813141 Free PMC article.
Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.
Talaat KR, Alaimo C, Martin P, Bourgeois AL, Dreyer AM, Kaminski RW, Porter CK, Chakraborty S, Clarkson KA, Brubaker J, Elwood D, Frölich R, DeNearing B, Weerts H, Feijoo BL, Halpern J, Sack D, Riddle MS, Fonck VG. Talaat KR, et al. Among authors: bourgeois al. EBioMedicine. 2021 Apr;66:103310. doi: 10.1016/j.ebiom.2021.103310. Epub 2021 Apr 13. EBioMedicine. 2021. PMID: 33862589 Free PMC article. Clinical Trial.
133 results